UCB, a Brussels-based biopharma company, announced plans to build a $2 billion biologics manufacturing hub in Gwinnett County, Georgia, to anchor U.S. production and strengthen its portfolio and pipeline.

The 460,000-square-foot facility will sit on 79 acres near Rowen Parkway, making UCB the anchor tenant of a 2,000-acre Rowen knowledge campus near Highway 316 between Atlanta and Athens.

UCB’s U.S. presence already includes a Smyrna headquarters, a Boston-area research site, and clinical R&D in Raleigh-Durham, with about 2,000 U.S. employees and more than 9,000 globally.

Sustainability is central to the project, emphasizing efficient design, advanced automation, and a reduced environmental footprint.

The Rowen project marks a shift from planning to active execution, reinforcing Rowen’s role as a collaborative hub for researchers, entrepreneurs, and industry partners.

Rowen will tap a broad local talent pipeline from nearby universities, leveraging existing infrastructure and upcoming facilities like the Rowen Convergence Center, with its first global tenant secured.

UCB leadership says the project aligns with a strategy of investing ahead of demand, maintaining flexibility, and delivering patient value across research, development, and manufacturing.

The Gwinnett site will be a cornerstone of UCB’s biologics network, reinforcing supply resilience through digital and sustainable practices.

Rowen envisions continued momentum with more than 1,900 acres still available for future tenants and expansion as it becomes a broader R&D and clean manufacturing destination.

The Gwinnett project will complement UCB’s global and U.S. contract manufacturing network to enable scale while maintaining quality.

Georgia offers incentives such as income tax credits, sales tax waivers on equipment purchases, and state-funded training to support the project.

The project will leverage advanced technologies like AI, robotics, and automation to enhance production quality, efficiency, and end-to-end manufacturing capabilities.